Comparative Pharmacology
Head-to-head clinical analysis: CYCLESSA versus ENPRESSE 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYCLESSA versus ENPRESSE 21.
CYCLESSA vs ENPRESSE-21
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of estrogen (ethinyl estradiol) and progestin (desogestrel) inhibits ovulation by suppressing gonadotropin release, increases viscosity of cervical mucus to impede sperm penetration, and alters endometrial receptivity.
Combination oral contraceptive; suppresses gonadotropin release via estrogen-progestin negative feedback, preventing ovulation; alters cervical mucus and endometrial lining to inhibit sperm penetration and implantation.
One tablet (0.15 mg desogestrel/0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.
ENPRESSE-21 (ethinyl estradiol/norethindrone acetate) is an oral contraceptive. One tablet (0.035 mg ethinyl estradiol/0.5 mg norethindrone acetate) by mouth once daily for 21 days, followed by 7 placebo days.
None Documented
None Documented
Desogestrel: 38±13 hours (terminal); ethinyl estradiol: 14±3 hours (terminal). Steady-state reached after 7-10 days.
Terminal elimination half-life is 8-10 hours; this supports once-daily dosing and reaches steady state within 2-3 days.
Urine (50-60% as metabolites, <10% unchanged); feces (30-40% as metabolites); enterohepatic circulation.
Renal excretion of unchanged drug accounts for approximately 30-40% of the dose; hepatic metabolism accounts for the remainder, with metabolites eliminated in bile and feces.
Category C
Category C
Oral Contraceptive
Oral Contraceptive